TRPC6 (transient receptor potential cation channel subfamily C member 6)

Class

Oral small-molecule TRPC6 ion-channel inhibitor

Pathway

Podocyte calcium signaling; TRPC6-variant-driven focal segmental glomerulosclerosis (FSGS)

TRPC6 is a calcium-permeable ion channel located in podocytes, the specialized cells that form part of the kidney's glomerular filtration barrier. Podocytes rely on tightly controlled calcium signaling to maintain their intricate cytoskeletal architecture, which is essential for filtering blood while retaining proteins. Certain inherited mutations make TRPC6 overly active, allowing excess calcium into podocytes. This disrupts the cytoskeleton, causes podocyte injury and detachment, and leads to focal segmental glomerulosclerosis (FSGS), a pattern of scarring within glomeruli that produces heavy protein loss in urine and progressive kidney function decline. Beyond inherited forms, TRPC6 activity is also implicated more broadly in proteinuric kidney diseases, since mechanical stress and certain hormonal signals occurring during glomerular injury can increase channel activity even without a mutation. An oral small-molecule inhibitor of TRPC6 is designed to reduce this excess calcium influx, aiming to protect podocyte structure, limit proteinuria, and slow the progression of glomerular scarring. This mechanism sits within a broader pathway of podocyte calcium signaling that researchers view as a shared vulnerability across multiple forms of glomerular disease, not just the genetic variant-driven cases.